Ethanol extract of Cnidii Rhizoma ameliorates dextran sulfate sodium-induced ulcerative colitis by inhibiting JNK/NF-κB signaling

Yo-Han Han¹,†, Dae-Seung Kim²,†, Ji-Ye Kee¹, Jung-Geon Mun¹, Hee-Dong Jeon¹, and Seung-Heon Hong¹

¹Department of Oriental Pharmacy, College of Pharmacy, Wonkwang-Oriental Medicines Research Institute, Wonkwang University, 460 Iksandae-ro, Iksan, Jeonbuk 54538, Republic of Korea

²Pharmaceutical Safety Evaluation Division, Pharmaceutical Safety Bureau, Ministry of Food and Drug Safety, Cheongju, Korea.

Correspondence to: Prof. Seung-Heon Hong, Department of Oriental Pharmacy, College of Pharmacy, Wonkwang-Oriental Medicines Research Institute, Wonkwang University, 460 Iksandae-ro, Iksan, Jeonbuk 54538, Republic of Korea. Tel: (+82) 63-850-6805, Fax: (+82) 63-843-3421, E-mail: jooklim@wku.ac.kr

†These authors contributed equally to this work.

Running title: Cnidii Rhizoma inhibit colitis via JNK/NF-κB signaling
Abstract: In this study, dextran sulfate sodium (DSS)-induced in vivo model and LPS-stimulated in vitro model were used to confirm whether ethanol extract of Cnidii Rhizoma (EtCR) could ameliorate UC. EtCR improved symptoms of UC, including body weight loss, colon length shortening, disease activity index (DAI), and colon mucosal damage. In addition, EtCR decreased inflammatory mediators, including cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS), in colon tissue. To further confirm the UC improving mechanism, RAW 264.7 cells and HT29 human epithelial cells were used. EtCR reduced expression of inflammatory cytokines (IL-1β, TNF-α, and IL-6) and inflammatory mediators (nitric oxide and prostaglandin E2) via JNK and NF-κB signaling pathway in RAW 264.7 cells. In addition, EtCR increased expression of trefoil factor 3 (TFF3), which is an epithelial cell protective factor, in HT29 cells. Taken together, our study suggests that EtCR has treatment effect on UC and can be a therapeutic agent.

Keywords: Cnidii Rhizoma; DSS; inflammation; NF-Kb; MAPKs; TFF3
1. Introduction

Ulcerative colitis (UC) is a chronic and multifactorial inflammatory bowel disease (IBD), which is mainly occurred in the rectum and colon [1]. Nevertheless UC is not life-threatening in itself, it has been reported that chronic recurrence of UC could increase the risk of colorectal cancer, which is the third most common cancer in the world [2]. Several drugs such as aminosalicylic acid drugs, immune suppressor, and hormone agents have been used to treat UC. However, many people are still suffered from high recurrence rates of UC and side-effects of drugs [3]. Although the etiologies of UC and a lot of therapies have been studied, it is very difficult to treat because of recurrence and other unknown reasons.

Among the various causes of UC, pro-inflammatory cytokines, which are mainly secreted from macrophages, T cells and epithelial cells, is certainly thought as a crucial factor in the treatment of UC. Since recurrence of intestinal inflammation is related to an abnormal immune response, cytokines can be an important mediator to control the intestinal immune system [4]. In patients with UC, increased level of pro-inflammatory cytokines including IL-1β, IL-6, and TNF-α have observed and expression of these cytokines are regulated by many kinds of intracellular proteins [5,6]. Among them, mitogen-activated protein kinases (MAPKs), including extracellular signal-regulated kinases (ERKs), the c-Jun N-terminal kinases (JNKs) and the p38 MAPK, are participated in inflammatory response by producing inflammatory mediators [7]. These signaling pathways can regulate inflammation by converting extracellular stimuli into the intracellular signaling, which induce the expression of inflammation related genes [8].
Nuclear factor-kappa B (NF-κB), which is one of the downstream factor of MAPKs, is also crucial factor for treatment of UC. It has been reported that patients with UC show strongly activated NF-κB in colon tissues [9]. NF-κB is consisted of p50 and p65, which normally exist in cytoplasm with inhibitor of NF-κB (IκB) [10]. By extracellular stimuli, IκB is degraded and phosphorylated through ubiquitin/proteasome pathway, and then NF-κB is activated. Activated NF-κB is subsequently translocated into nucleus to bind with sequence of target genes [11]. Translocated NF-κB can regulate transcription of inflammation related genes, including cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS) [10]. COX-2, which is induced by inflammatory stimuli such as arthritis, asthma and IBD, contributes to not only the pain and swelling, but also converting of arachidonic acid to prostaglandin E2 (PGE2) [12-14]. Another downstream target of NF-κB is iNOS, which leads vasodilation of inflammatory cells easily [15]. iNOS is highly expressed in inflamed intestine mucosa and induces tissue damage by generating nitric oxide (NO) [16]. Therefore, suppressing NF-κB activation through MAPKs cascades is crucial for treating colitis.

Intestinal epithelium exhibits barrier function against luminal antigens. The intestinal epithelium is composed of a single epithelial cell layer. This layer is covered by mucus, which protects epithelial layer by distinguishing from mucosal bacteria [17]. To protect the intestine from bacterial infection and damage, epithelial cells secrete anti-microbial peptides into mucus [18]. Anti-microbial peptides are regulated by trefoil factor 3 (TFF3). TFF3, which is synthesized in the goblet cells of the small and large intestine, plays important roles in the protection and repair of epithelial surfaces, including the gastrointestinal tract [19].

In this study, we used rhizomes of Cnidium officinale Makino (Cinidii Rhizoma; CR). Cnidium officinale Makino is extensively cultivated and it has been used as medicine in East
Asia [20]. Since CR contains 1-2 % of essential oil and several compounds, it has shown various pharmacological effects such as muscle relaxing, anti-tumor, anti-anemia, and anti-metastatic effects [21]. In particular, CR has been previously reported that improvement of blood circulation and anti-inflammatory effects [22]. However, there is no report on the therapeutic effect of CR on UC. Therefore, this study investigated that improvement effect of CR on colitis in *in vitro* and *in vivo*. 
2. Results

2.1. EtCR Prevents Symptoms of Colitis in DSS-induced Colitis Mice

To estimate whether EtCR could inhibit progression of colitis, mice were administrated 5% DSS containing water with or without EtCR (50 mg/kg/day) and 5-ASA (50 mg/kg/day). As shown in Figure 1A, administration of DSS decreased body weight compared to control group. However, administration of EtCR inhibited weight loss similarly with 5-ASA, which is treatment drug of colitis. Also, the severity of colitis was presented by DAI score, which concerned other factors, including bleeding and diarrhea, as well as body weight. As shown in Figure 2B, DAI score of DSS group was steadily increased from day 5 to day 7. However, EtCR and 5-ASA treated groups showed better DAI score compared to only DSS-treated group. Since Shortening of colon length is closely related to the increased DAI scores [24], we measured colon length after sacrificing the mice. Similarly with DAI scores, EtCR and 5-ASA suppressed the reduction of colon length (Figure 1C,D). Furthermore, enlarged spleen was observed in DSS-treated mice, whereas administration of EtCR and 5-ASA decreased the size of spleen (Figure 1E). These results suggest that EtCR ameliorate DSS-induced colitis similar to 5-ASA.

2.2. EtCR Inhibits Colon Tissue Damages Induced by DSS

Since the administration of DSS induces colon tissue damages, including loss of epithelial layer, infiltration of inflammatory cells into the mucosa, and loss of goblet cells [25], we conducted H&E staining and alcian blue staining to confirm colonic protective effect of EtCR from DSS induced damages. As shown in Figure 2A, morphology alterations were
observed. Epithelial layer were almost eroded and crypt architecture were not found in DSS-treated colon tissue. In addition, infiltration of inflammatory cells was also shown in DSS-treated group. However, administration of EtCR and 5-ASA reduced not only damages of colon tissue, but also infiltration of inflammatory cells. To compare the degree of inflammation, we assessed the each group of H&E stained images and assigned scores. The scores indicated that administration of EtCR relieved severity of colitis. (Figure 2B). In addition, administration of EtCR inhibited the expression of COX-2 and iNOS, which are inflammatory factors increased by DSS (Figure 2E,F). Next, we confirmed goblet cells, which secrete a mucosal protective substance [26]. To stain goblet cells, alcian blue staining was conducted. As shown in Figure 2C, blue spots were well-shown in colon tissue of control group and it was seldom seen in DSS-treated group. In EtCR and 5-ASA-administrated groups, the blue stained cells were increased in colon tissues (Figure 2D). Furthermore, the TFF3 expression was recovered in EtCR and 5-ASA-administrated groups, compared with DSS-treated group (Figure 2E,G). Therefore, these results indicated that the EtCR could ameliorate colitis by protecting colon tissue.

2.3. EtCR Regulates LPS-stimulated Cytokine and Pro-Inflammatory Mediators in in vitro

To confirm whether EtCR could regulate inflammatory reaction, RAW 264.7 cells were used in this study. Since regulation of pro-inflammatory cytokines such as IL-1β, TNF-α and IL-6 is important in inflammation related diseases [27], we investigated whether EtCR has anti-inflammatory effects in LPS-stimulated RAW 264.7 cells. To determine the experimental dose of EtCR in RAW 264.7 cells, the cells were treated with 1, 10, and 100 μg/ml of EtCR. Since
EtCR did not show significant cytotoxicity up to 100 μg/ml of EtCR (Figure 3A), we used 100 μg/ml of EtCR as a highest concentration. As shown in Figure 3B-D, EtCR reduced the productions of IL-1β, TNF-α, and IL-6, compared to LPS treated group.

2.4. EtCR Decreases LPS-induced NO and PGE₂ by Suppressing iNOS and COX-2 in RAW 264.7 Cells

It has been reported that colon tissue damages induced by colitis is related to inflammatory mediators [28]. Thus, reducing the pro-inflammatory mediators as well as cytokines is also crucial for colitis. As shown in Figure 4A,B, pre-treatment of EtCR decreased levels of NO and PGE₂, which were elevated by LPS. In addition, we investigated expression levels of iNOS and COX-2, which produce NO and PGE₂, respectively. Similarly with the tendency of NO and PGE₂, EtCR reduced the expressions of iNOS and COX-2 (Figure 4C,D).

2.5. EtCR Reduces Inflammation Through NF-κB and MAPKs in RAW 264.7 Cells

NF-κB pathway regulates various inflammatory mediators. NF-κB exists in the cytoplasm in an inactive form with IκB. After inflammatory stimulation, IκB are phosphorylated and degraded. Continuously, NF-κB is translocated into the nucleus and leads to inflammatory responses [29]. As shown in Figure 5A,B, IκB in the cytoplasm was phosphorylated and degraded by LPS stimulation, which is an inflammatory stimulus. And then, NF-κB p65 was translocated into the nucleus. However, the treatment of EtCR suppressed this signaling pathway. In addition, the result of NF-κB binding assay showed that the EtCR
treatment effectively reduced the NF-κB binding activity, dose dependently (Figure 5C). It was also reported that the NF-κB signaling is regulated by MAPKs, including ERK, JNK, and p38 [30]. As shown in Figure 5D and E, EtCR inhibited LPS-induced phosphorylation of JNK, whereas ERK and p38 phosphorylation was not suppressed by EtCR. These results suggested that EtCR inhibited the inflammatory response by inhibiting JNK and NF-κB signaling pathway.

2.6. EtCR Regulates TFF3 in HT 29 cells

To confirm whether EtCR recovered the expression of TFF3, we used HT29 known as colonic epithelial cells. Since HT29 cells show properties of pluripotent intestinal cells, they are commonly used to investigate intestinal epithelial circumstance [31]. In our experiment, TFF3 was fully expressed in HT29 cells, but this expression was inhibited by LPS treatment. However, the treatment of EtCR increased TFF3 in both protein and mRNA level without cytotoxicity (Figure 6). Thus, these results indicate that EtCR could ameliorate colitis by protecting the epithelial cells of the intestine.
UC and Crohn’s disease (CD) are the two most common forms of IBD, which is characterized by a chronic inflammation of intestine. The etiologies of both diseases are unclear. However, main cause of these diseases is considered to multifactorial, including environmental factors such as smoking and western diet, the genetic factors and the intestinal flora [32]. Although the symptoms between UC and CD are similar in many parts, there are also slightly different. People suffering from UC have the abdominal pain in the left side of the abdomen, while suffering from CD have abdominal pain in their all abdomen. It has been known that CD is more severe than UC, but the incidence of CD is much lower than UC [33]. In addition, the treatment drugs of UC, including 5-ASA and glucocorticoids, occurred side-effects such as arthralgia, myalgia, headache, and abdominal pain [34]. Therefore, our study focused on UC rather than CD and suggested the new therapeutic agents of UC using natural products with few side effects.

EtCR is expected that could improve colitis through several research findings about EtCR. It has been reported that the health functional food containing CR improved TNBS-induced colitis and histological changes such as thickening, dilatation, ulceration, and infiltration [35]. In addition, CR had anti-inflammatory effect by reducing NO production in LPS-stimulated BV-2 microglia cell [36]. Despite these possibilities, there was no report on the effect of EtCR on UC. In this study, we confirmed whether EtCR can ameliorate UC, using DSS-induced colitis model. Since the symptoms, including weight loss, bloody stool, damages of colon tissue, colon shortening, and diarrhea, of this model are similar with human UC, it is often used to colitis experiment [37]. In our experiment, administration of DSS reduced body weight, which indicates DSS induced colitis. However, the administration of EtCR significantly inhibited
weight loss compared to DSS-treated group (Figure 1A). In addition, DAI scores and colon shortening were improved by administration of EtCR (Figure 1B-D). It has been also reported that the weight of spleen, which can produce inflammatory cytokines, was increased in DSS-treated mice [38]. As shown in Figure 1E, the spleen weight was increased by DSS treatment, whereas EtCR inhibited enlargement of spleen. In particular, EtCR exerted the similar therapeutic effect as 5-ASA, which is a treatment drug of UC (Figure 1).

In normal condition, epithelial cell layer secretes protective substances to colon to maintain colon condition. However, it cannot be secreted because of collapse of cell layer in colitis [39]. Therefore, symptoms such as diarrhea and bleeding are accompanied. Furthermore, the weakened epithelial cell layer allows immune cells to infiltrate into the intestinal lumen [40].

In our experiment, administration of DSS almost eroded epithelial layer and crypt. Inflammatory cell infiltration also found in colon tissue of DSS-treated group. However, EtCR protected DSS-inducing mucosal erosion, disruption of intestinal crypts as well as inflammatory cell infiltration (Figure 2A,B). We also confirmed goblet cell, which are abundant in colon tissue and secreted protective mediators [41]. As shown in Figure 2C, blue spots were well-shown in normal colon tissue, which is seldom seen in DSS-treated group. However, the blue positive cells were increased in the colon tissue of 5-ASA group as well as EtCR-administrated group (Figure 2C,D). Accordance with result of alcian blue staining, the expression of TFF3, which is a constituent of mucus and is produced from goblet cell in large intestine, was decreased in the colon tissue of DSS-treated group, but it was recovered by EtCR administration (Figure 2E,G). These structural changes are known to be closely associated with inflammatory reactions, and the inflammatory factors such as COX-2 and iNOS are found in almost UC patients [42]. Similarly with clinical case, expressions of COX-2 and iNOS were
elevated in DSS-treated group. However, administration of EtCR reduced expression of COX-2 and iNOS in colon tissue (Figure 2E,F). As a result, EtCR improved colitis in \textit{in vivo} experiment, and the therapeutic effect of EtCR is slightly lower than 5-ASA.

To further investigate the underlying anti-inflammatory mechanisms of EtCR, we confirmed pro-inflammatory mediators in LPS-stimulated RAW 264.7 cells. The stimulated macrophages secrete large amounts of IL-1, IL-6, and TNF-α [43]. Since the increased expressions of pro-inflammatory cytokines such as IL-1, IL-6, IL-8, and TNF-α are also detected in UC patients [5,6], this \textit{in vitro} model was used to investigate the anti-inflammatory mechanism of EtCR. Falcarindiol, 6-hydroxy-7-methoxy-dihydroligustilide, ligustilidiol, and senkyunolide H were isolated from methanol extract of CR and they showed inhibitory effects on iNOS and COX-2 expression in LPS-stimulated RAW 264.7 cells [44]. In our experiment, LPS-stimulated RAW 264.7 cells secreted pro-inflammatory cytokines, but EtCR treatment reduced the production of IL-1β, TNF-α, and IL-6 (Figure 3). Similar to \textit{in vivo} results, the expressions of iNOS and COX-2 were inhibited by EtCR. In addition, the production of NO and PGE$_2$, which are produced by iNOS and COX-2, were also decreased by EtCR (Figure 4). Thus, it is quite convincing that therapeutic effect on UC may come from anti-inflammatory properties of EtCR.

Ethanol extract of \textit{Cnidium officinale} Makino showed anti-inflammatory effects by blocking NF-κB pathway in BV2 microglial cells [45]. Therefore, we confirmed whether EtCR can regulate anti-inflammatory factors via NF-κB pathway in RAW 264.7 cells. NF-κB is plays a critical role in the immune system, which controls the expression of enzymes and cytokines during inflammatory responses [46]. In normal condition, NF-κB binds to its inhibitor IκB, and could not translocate to the nucleus. Once IκB is phosphorylated by IKK, IκB is degraded and
NF-κB undergoes nuclear translocation, and it triggers the expression of pro-inflammatory genes [47]. Therefore, we investigated IκB phosphorylation and NF-κB translocation. Based on our results, LPS treatment induced phosphorylation of IκB and nuclear translocation of NF-κB, but EtCR decreased IκB phosphorylation and NF-κB translocation (Figure 5A,B). Furthermore, the binding NF-κB to the nucleus induced by LPS was inhibited by EtCR (Figure 5C). Moreover, we confirmed expression of MAPKs in EtCR-treated cells, because the activation of MAPKs have been known to regulate NF-κB as an upstream factors [48]. In this study, EtCR treatment attenuated LPS-induced phosphorylation of JNK, but not ERK and p38 (Figure 5D,E). These results showed that EtCR inhibited the expression of inflammatory mediators through JNK and NF-κB pathway. From this result, the inhibitory effect of EtCR on DSS-induced colitis was considered to the regulation of JNK and NF-κB signaling pathway.

To confirm expression level of TFF3, LPS-stimulated human epithelial cell line HT29 was used. Once mucosal layer is depleted, epithelial cells are exposed directly to luminal contents such as bacteria and their metabolites [49]. In this experiment, LPS was used as an inflammatory stimulator to intestinal epithelial cells. It has been known that LPS reduces TFF3 expression by activating NF-κB in HT29 cells [50]. Consistent with this report, LPS inhibited the expression of TFF3, but treatment of EtCR on HT29 cells recovered the expression of TFF3 (Figure 6).
4. Experimental Section

4.1. Reagents and Antibodies

5-aminosalicylic acid (ASA), dimethyl sulfoxide (DMSO), triton-X, alcian blue, eosin, neutral buffered formalin, and lipopolysaccharides (LPS) were obtained from Sigma-Aldrich (St. Louis, MO, USA). Skim milk was purchased from BD Difco Laboratories (Detroit, MI, USA). Gill’s hematoxylin V was purchased from Muto Pure Chemicals (Tokyo, Japan). Xylene was purchased from Dae-Jung chemicals (Siheung, Republic of Korea). Dextran sulfate sodium (DSS) (mol wt: 36,000 – 50,000) was purchased from MP Biomedicals (Solon, OH, USA). Dulbecco’s Modified Eagles Medium (DMEM), fetal bovine serum (FBS), and phosphate-buffered saline (PBS) were obtained from WELGENE (Gyeongsan, Republic of Korea). The anti-rabbit IgG, anti-mouse IgG, and anti-goat IgG antibodies were purchased from Jackson ImmunoResearch Laboratories (West Grove, PA, USA). Mouse TNF-α, IL-1β, and IL-6 enzyme-linked immunosorbent assay (ELISA) kits were purchased from BD Biosciences (Mountain View, CA). Antibodies against COX-2, iNOS, p38, ERK, JNK, NF-κB, PCNA, IκB, phospho-IκB, and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Phospho-p38, phospho-ERK, and phospho-JNK were purchased from Cell Signaling Technology, Inc. (Danvers, MA, United States). TFF3 antibody was purchased from Invitrogen (Carlsbad, CA, USA).

4.2. Ethanol Extract of CR (EtCR)

CR was purchased from Omnitherb (Uiseong, Republic of Korea). EtCR was obtained by extracting dried 100 g of CR in 1 liter of 70% ethanol for approximately 3 h in heating mantle.
with reflux condenser. After eliminating solvent with rotary evaporator under reduced pressure (Rotary evaporator Model NE-1, Tokyo, Japan), the remnant was filtered and lyophilized (Freeze dryer FD-1, Japan) at -56°C and 9 mm Torr to acquire herbal sample. The yield from the starting material was about 5%. The obtained sample was diluted using ethanol and then filtered through a 0.22-µm syringe filter.

4.3. Induction of DSS-induced Colitis in Mouse Model

Female BALB/c mice (6 weeks old) were purchased from Samtaco Science (Osan, Republic of Korea). Before inducing colitis, mice were maintained in experimental environment (22 ± 2°C under a 12-h light/dark cycle) for one week. To induce colitis in mice, drinking water containing 5% (w/v) DSS is given for seven days. Mice were randomly divided into four groups (n = 8): the control group were fed drinking water without DSS, the DSS group fed drinking water with DSS, the EtCR group fed drinking water with DSS and oral administration of EtCR (50 mg/kg), and the 5-ASA group fed drinking water with DSS and oral administration of 5-ASA (50 mg/kg; a reference drug). EtCR and 5-ASA were suspended in 0.3% CMC water. EtCR and 5-ASA were orally administered daily during 7 days. Control group and DSS group were administered with the same volume of water. Drugs were simultaneously administrated with the DSS treatment. After 7 days, mice were sacrificed and colon length and spleen weight were measured. All experiments were carried out in accordance with the regulations issued by the Institutional Review Board of Wonkwang University (WKU15-82).
4.4. Disease Activity Index (DAI)

DAI was calculated by scoring weight loss, diarrhea, and rectal bleeding. Each score was assessed as shown in Table 1, which was described by Murthy et al [23]. Briefly, weight loss was determined as the difference between initial and final weights. Diarrhea was evaluated to degree of the fecal pellet formation. Rectal bleeding was assessed based on the presence of visible blood. After calculation using the following formula, DAI were recorded: 

$$\text{DAI} = \frac{\text{weight loss score} + \text{diarrhea score} + \text{rectal bleeding score}}{2}.$$ 

4.5. Colon Tissue Staining and Evaluation of Colitis Severity

All resected colon tissues were fixed in 10% neutral buffered formalin for 24 hours. After paraffin embedding, samples were sectioned to 5 μm. The sections were stained with hematoxylin and eosin (H&E) and Alcian blue/Nuclear Fast Red. Each stained images were captured by Leica Application Suite MicroSoftware (Leica Microsystems Inc, IL, USA). Histological scores were based on epithelium and infiltration. The damages of epithelium were determined as follows: Normal morphology; 0, loss of goblet cells; 1, loss of goblet cells in large areas; 2, loss of crypts; 3, loss of crypts in large areas; 4. Infiltration of mucosal immune cell were determined as follows: no infiltrate; 0, infiltrate around the crypt basis; 1, infiltrate reaching the L. muscularis mucosae; 2 extensive infiltration reaching the L. muscularis mucosae and thickening of the mucosa with abundant edema; 3, infiltration of the L. submucosa; 4. The total histological score was given as sum of epithelium and infiltration.
Alcian Blue positive cells were counted in ten random areas using microscope (Leica, Wetzlar, Germany).

4.6. Cell Culture

RAW 264.7 cells and HT29 cells were purchased in Korean cell line bank (Seoul, Republic of Korea). The cells were cultured at 37°C under 5% CO₂ in 10% FBS/DMEM supplemented with 1% penicillin/streptomycin. The cells were pretreated with 1, 10, and 100 μg/mL of EtCR for 1 h, and then stimulated with 200 ng/mL of LPS for 24 h. EtCR was diluted by ethanol whose final concentration was below 0.1%.

4.7. Cell Viability

Cell viability was determined by 3-(4,5-dimethylthiazol-2-yl)-diphenyltetrazoliumbromide (MTT) assay. Briefly, RAW 264.7 and HT29 cells were seeded in 24-well plates at 3 × 10⁵ cells/well and the cells were incubated with various concentrations of EtCR. After 24 h, 5 mg/mL of MTT solution was treated for 4 h in incubator. After washing off the supernatant, the insoluble formazan product was dissolved in DMSO and loaded into 96-well microplate. The absorbance was measured at 540 nm with a VERSA max microplate reader (Molecular Devices, Sunnyvale, CA, USA).

4.8. Cytokine Assay
To confirm the cytokine production from EtCR and LPS treated cells, $3 \times 10^5$ cells were seeded into 24-well plates. Various concentrations of EtCR were pretreated for 1 h prior to 24 h treatment with 200 ng/mL LPS. And then, cytokines, including IL-1β, IL-6, and TNF-α, were confirmed using supernatant. The production levels of IL-1β, IL-6, and TNF-α were confirmed using ELISA kits, according to the manufacturer’s instructions.

4.9. NO Assay

RAW 264.7 cells were seeded ($5 \times 10^5$ cell/well) and incubated with EtCR and LPS as already described in our study. To measure the NO content in the culture supernatant, Griess Reagent (1% sulfanilamide/0.1% N-(1-naphthyl)-ethylenediamine dihydrochloride/2.5% H$_3$PO$_4$) was used. Equal volume of supernatant and Griess reagent were incubated for 10 minutes at room temperature. The NO$^2$ level in supernatant was determined using sodium nitrite as a standard and the absorbance was measured by a microplate reader at a wavelength of 540 nm.

4.10. PGE$_2$ Assay

To measure the amount of PGE$_2$, $5 \times 10^5$ of RAW 264.7 cells were seeded in 24-well plated and treated with EtCR and LPS. The PGE$_2$ concentration was calculated using a PGE$_2$ ELISA kit (Enzo Life Sciences, USA) according to the manufacturer’s directions.

4.11. Western Blot Analysis
RAW 264.7 cells (5 × 10^6 cell/well) and HT29 cells (5 × 10^6 cell/well) were cultured in 6 cm dish. EtCR and LPS were treated as already described in our study. The cells were washed with PBS and then lysed by lysis buffer (iNtRON Biotech, Seongnam, Republic of Korea). Nuclear extracts were isolated using the NE-PER Nuclear and Cytoplasmic Extraction Reagents kit (Thermo Fisher Scientific, Waltham, MA, United States) according to the manufacturer's protocols. The cell lysates were mixed with an equal volume of 2 × SDS sample buffer and boiled at 95 °C for 5 min. The samples were loaded and separated by SDS-page gels. After electrophoresis, the proteins were transferred onto PVDF membranes and divided according to the size of each target proteins. The membranes were blocked by 5% skim milk for 2 hours and incubated with primary antibodies overnight at 4°C. After washing the membrane with 0.1% PBST 5 times, the membranes were incubated with horseradish peroxidase-conjugated secondary Abs for 1 hour. The membranes were washed with PBST 5 more times and the protein bands were visualized by ECL solution. Images were captured using the FluorChem E system (ProteinSimple, San Jose, CA, USA).

### 4.12. NF-κB Binding Assay

The nuclear extract was incubated with an immobilized oligonucleotide on a 96-well plate containing a specific NF-κB binding site and detected by a specific p65 NF-κB subunit ELISA kit (Affymetrix, Santa Clara, CA, USA), according to the manufacturer’s instructions.

### 4.13. Real-time RT-PCR
Total RNA was extracted from the cells using an Easy-Blue total RNA extraction kit (iNtRON Biotech, Republic of Korea) according to the manufacturer’s instructions. First-strand cDNA was reverse-transcribed using 2 μg of RNA and an Accupower® RT PreMix (Bioneer, Daejeon, Republic of Korea). The primers of TFF3 and GAPDH were used for real-time PCR analysis. Real-time PCR was performed using a Power SYBR® Green PCR Master Mix and a StepOneplus Real-Time PCR System (Applied Biosystems, Foster City, CA, USA). All data were normalized to GAPDH mRNA. Sequences of the primers used for human genes were as follows: TFF3, 5’-CTCCAGCTCTGCTGAGGAT-3’, 5’-CAGGGATCCTGGAGTCAA-3’; GAPDH, 5’-CGGAGTCAACGGATTGTGCG-3’, 5’-AGCCTTCTCCATGGAAGAC-3’.

4.14. Statistical analysis

The results are expressed as the mean ± S.D. of independent experiments. Statistical evaluations were performed by a one-way analysis of variance (ANOVA) with Tukey’s multiple comparison test. All statistical analyses were computed by SPSS statistical analysis software version 12.0 (SPSS Inc., Chicago, IL, United States). Values of $p < 0.05$ were considered to represent significant differences.

5. Conclusions

Our study demonstrated that EtCR ameliorated UC in DSS-induced mice and protected epithelial cell layer by recovering expression of TFF3. EtCR inhibited inflammatory factors in
colon tissue. In *in vitro* experiment, EtCR inhibited inflammatory factors, including iNOS and COX-2, through JNK and NF-κB pathway. In addition, EtCR regulated TFF3 in colon epithelial cells. EtCR is expected to have fewer side effects because it is derived from natural products. Based on these results, EtCR could be therapeutic agent and alternative supplement for UC.
Acknowledgments: This paper was supported by Wonkwang University in 2017.

Author Contributions: Y.-H.H. participated in the study design, analyzed the data and wrote the manuscript. D.-S.K. carried out the experiments. J.-Y.K. provided technical and material support. J.-G.M., and H.-D.J. performed the experiments and analyzed the data. S.-H.H. designed and supervised the study, including editing of the manuscript. All authors contributed to and have approved the final manuscript.

Conflicts of Interest: The authors declare no conflict of interest.
References


17. Swidsinski, A.; Ladhoff, A.; Pernthaler, A.; Swidsinski, S.; Loening-Baucke, V.; Ortner,


Figure captions

**Figure 1.** The Effect of EtCR on DSS-induced colitis. UC was induced by 5% DSS in the drinking water for 7 days. During this period, EtCR (50 mg/kg) and 5-ASA (50 mg/kg) were orally administrated once a day. (A) Body weight changes were measured. (B) Disease activity index was investigated for the last 3 days. (C) The representative images of colon tissue were shown. (D) Colon lengths were measured after sacrificing the mice. (E) Spleen weights were measured. Values represent mean ± S.D. Data were analyzed by one-way ANOVA (#p < 0.05 vs. control, *p < 0.05 vs. DSS alone).

**Figure 2.** The Effect of EtCR on colon tissue damage and inflammation in colitis. (A) Representative H&E staining images of colon tissue were observed by microscope (magnification 100× and 200×). Scale bar = 200 μm. (B) Histological score was calculated as described in materials and methods. (C) Colon tissues were stained with alcian blue (magnification 100× and 200×). Scale bar = 200 μm. (D) Goblet cells stained with alcian blue were counted. (E) The protein expressions (COX-2, iNOS, and TFF3) were determined by western blot using colon tissue. (F and G) Relative protein levels were normalized to GAPDH and measured using Image-J. Values represent mean ± S.D. Data were analyzed by one-way ANOVA (#p < 0.05 vs. control, *p < 0.05 vs. DSS alone).

**Figure 3.** The Effect of EtCR on cytokines LPS-stimulated RAW 264.7 cells. Cells were pre-treated with of EtCR for 1 h and then stimulated with LPS (200 ng/ml) for 24 h. (A) Cytotoxicity of EtCR was measured using MTT assay. (B-D) Concentrations of IL-1β, TNF-α,
and IL-6 were measured by ELISA kit using cell supernatants. Values are the mean ± S.D. Data were analyzed by one-way ANOVA (#p<0.05 vs. untreated cells, *p<0.05 vs. LPS-stimulated cells).

Figure 4. The Effect of EtCR on productions of NO and PGE$_2$ and the expressions of iNOS and COX-2 in LPS-stimulated RAW 264.7 cells. Cells were pre-treated with of EtCR for 1 h and then stimulated with LPS (200 ng/ml) for 24 h. (A) The amount of NO production was measured by the Nitrite Assay. (B) The amount of PGE$_2$ production was measured using the PGE$_2$ assay kit. (C) The expression of iNOS was determined by a western blot and band intensity was measured using Image-J. (D) The expression of COX-2 was determined by a western blot and band intensity was measured using Image-J. Values are the mean ± S.D. Data were analyzed by one-way ANOVA (#p<0.05 vs. untreated cells, *p<0.05 vs. LPS-stimulated cells).

Figure 5. The Effect of EtCR on NF-κB and MAPKs in LPS-stimulated RAW 264.7 cells. Cells were pre-treated with EtCR for 1 h, and then stimulated with 200 ng/ml of LPS for 30 min. The nuclear extracts were evaluated for NF-κB expression and cytosolic extracts were examined for IκB, p-IκB, and MAPKs expressions. (A) The expression levels of IκB, p-IκB, NF-κB, and PCNA were determined by western blot analysis. (B) Band intensities were normalized by GAPDH and PCNA using Image-J. (C) The NF-κB binding activity was determined by a NF-κB binding assay. (D) The expressions of p-JNK, JNK, p-ERK, ERK, p-p38, and p38 were determined by western blot analysis. (E) Intensities of p-JNK, p-ERK, and
p-p38 were normalized by JNK, ERK, and p38, respectively and measured using Image-J. Values are the mean ± S.D. Data were analyzed by one-way ANOVA (#p<0.05 vs. untreated cells, *p<0.05 vs. LPS-stimulated cells).

**Figure 6.** The effect of EtCR on TFF3 in HT29 cells. (A) Cell viability was measured by MTT assay. (B) The mRNA level of TFF3 was measured by real-time PCR. (C) The TFF3 expression was determined by a western blot analysis. Band intensities were normalized by GAPDH and were measured using Image-J. Values are the mean ± S.D. Data were analyzed by one-way ANOVA (#p<0.05 vs. untreated cells, *p<0.05 vs. LPS-stimulated cells).
Table 1. Criteria for Disease Activity Index (DAI)

<table>
<thead>
<tr>
<th>Score</th>
<th>Weight loss (%)</th>
<th>Stool consistency</th>
<th>Bloodstain or gross bleeding</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>None</td>
<td>Normal</td>
<td>Negative</td>
</tr>
<tr>
<td>1</td>
<td>1-5</td>
<td>Loose stool</td>
<td>Negative</td>
</tr>
<tr>
<td>2</td>
<td>5-10</td>
<td>Loose stool</td>
<td>Positive</td>
</tr>
<tr>
<td>3</td>
<td>10-15</td>
<td>Diarrhea</td>
<td>Positive</td>
</tr>
<tr>
<td>4</td>
<td>&gt;15</td>
<td>Diarrhea</td>
<td>Gross bleeding</td>
</tr>
</tbody>
</table>
Figure 1.
Figure 2.
Figure 3.
Figure 4.

(A) Nitric oxide (μg/ml)

(B) PDH level (mg/L)

(C) INOS

(D) COX2

[Graphs showing experimental results with LPS and EcCR (μg/ml) concentrations]
Figure 5.
Figure 6.
Graphical Abstract